Navigation Links
Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Date:7/16/2014

RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). The efficacy and safety of nintedanib in the treatment of IPF has not been established.

"Boehringer Ingelheim is proud that the FDA has granted Breakthrough Therapy designation for nintedanib, which will help expedite its development and review as a potential treatment option for patients with IPF," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to working with the FDA during the NDA review of nintedanib for people living with this serious and life-threatening lung disease, for which there are currently no FDA-approved treatment options."

The Breakthrough Therapy designation process was established by the FDA in 2012 and is intended to expedite the development and review of drugs for serious or life-threatening conditions, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

IPF is a serious and life-threatening lung disease that causes permanent scarring of the lungs, difficulty breathing and decreases the amount of oxygen the lungs can supply to the body. IPF affects as many as 132,000 Americans. There are currently no FDA-approved treatments.

Results from two global Phase 3 studies (INPULSIS™-1 and INPULSIS™-2) evaluating the efficacy and safety of nintedanib in the treatment of IPF were presented at the American Thoracic Society (ATS) International Conference and published in the New England Journal of Medicine in May 2014.

'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
2. Apollo Medical Holdings and Boehringer Ingelheim to Collaborate On Care of ApolloMed Accountable Care Organization (ACO) Patients with COPD
3. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
4. Boehringer Ingelheims Jeff Huth Elected as National Pharmaceutical Councils Chairman of the Board
5. Boehringer Ingelheims interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
6. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
7. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
8. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
9. Boehringer Ingelheims investigational volasertib receives FDA Breakthrough Therapy designation
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... YORK and LONDON , ... global orthopedic industry are expected to grow at an ... in terms of value and volume. Hip, knee and ... developed world while in emerging economies they have a ... rates are challenging the use of composites. Non-metallic orthopedic ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2
... Vermillion, Inc.,(OTC Bulletin Board: VRML) announced today that ... Strategic Alliance Agreement between the parties,through October, 2009. ... on the development and commercialization of two tests, ... to identify women with ovarian tumors that,are at ...
... bone mineral density at the,lumbar spine and total ... inhalation powder) and salmeterol, - Study provides ... patients,with COPD, PHILADELPHIA, Oct. 29 GlaxoSmithKline ... study of patients with,Chronic Obstructive Pulmonary Disease (COPD) ...
Cached Medicine Technology:Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 2Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 4Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3
(Date:12/26/2014)... 26, 2014 Parker & Sons, ... best in heating, cooling and plumbing contractor services ... emergency services in 2014 with regard to air-conditioning ... Arizona is known for its incredibly hot summers. ... the intricacies and details of a wide variety ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... tamoxifen, switching to an aromatase inhibitor within three years ... The study reveals that the clear survival benefit was ... other causes – a significant risk associated with tamoxifen. ... significant impact on the survival rates of women with ...
... top Spanish fashion show, the Pasarela Cibeles, has rejected five models ... said. ,"Some of the girls were rejected due to ... of being 1.80 meters and weighing less than 50 kg," said ... other doctors. ,Although some models reach the body mass ...
... Socrates is smiling. His move to lift a ban on abortion ... in favor of the ban being lifted or, legalizing abortion. ... catholic nations that prohibit abortion or destruction of unborn children, due ... up to 3 years prison term and those who aid them ...
... to be monitored more carefully according to reports sounded ... are at a higher risk of giving birth to still-born ... Bahtiyar of Yale School of Medicine, who put forward results ... study. ,It was seen that the risk of ...
... increases a woman’s risk of becoming infected with HIV, ... edition of The Journal of Infectious Diseases (now online). ... sexually transmitted infections increase the risk of transmission and ... of Trichomonas vaginalis per year worldwide, there are few ...
... at least 90 per cent copper completely eliminate E. coli ... properties of the metal. ,The study gives machine ... of metals they use to coat the insides of their ... eliminating E coli contamination in their products. E. Coli O157:H7 ...
Cached Medicine News:Health News:Early Switch to an Aromatase Inhibitor Increases Survival 2Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 2Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 3Health News:Copper Alloys Surfaces Touted As Pathogen Killers 2
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and ...
... Steri-Cult has been the ... high volume cell culture for ... Its the name that brought ... infrared CO 2 sensors,microprocessor ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
IR Autoflow Single Chamber Water-Jacketed CO2 Incubator...
Medicine Products: